2.Silencing GmWRKY33B genes leads to reduced disease resistance in soybean.
Chenli ZHONG ; Wenxu WANG ; Lina LIAO ; Jianzhong LIU
Chinese Journal of Biotechnology 2024;40(1):163-176
The WRKYs are a group of plant-specific transcription factors that play important roles in defense responses. In this study, we silenced 2 GmWRKY33B homologous genes using a bean pod mosaic virus (BPMV) vector carrying a single fragment from the conserved region of the GmWRKY33B genes. Silencing GmWRKY33B did not result in morphological changes. However, significantly reduced resistances to Pseudomonas syringae pv. glycinea (Psg) and soybean mosaic virus (SMV) were observed in the GmWRKY33B-silenced plants, indicating a positive role of the GmWRKY33B genes in disease resistance. Kinase assay showed that silencing the GmWRKY33B genes significantly reduced the activation of GmMPK6, but not GmMPK3, in response to flg22 treatment. Reverse transcriptase PCR (RT-PCR) analysis of the genes encoding prenyltransferases (PTs), which are the key enzymes in the biosynthesis of glyceollin, showed that the Psg-induced expression of these genes was significantly reduced in the GmWRKY33B-silenced plants compared with the BPMV-0 empty vector plants, which correlated with the presence of the W-boxes in the promoter regions of these genes. Taken together, our results suggest that GmWRKY33Bs are involved in soybean immunity through regulating the activation of the kinase activity of GmMPK6 as well as through regulating the expression of the key genes encoding the biosynthesis of glyceollins.
Glycine max/genetics*
;
Disease Resistance/genetics*
;
Biological Assay
;
Dimethylallyltranstransferase
;
Gene Silencing
3.Expression of CD226 in the small intestinal group 3 innate lymphoid cells (ILC3) in mice.
Lu YANG ; Jingchang MA ; Yitian LIU ; Tingting WANG ; Yuling WANG ; Ran ZHUANG ; Zhengxiang ZHANG
Chinese Journal of Cellular and Molecular Immunology 2024;40(1):1-6
Objective To observe the expression of adhesion molecule CD226 on the small intestinal group 3 innate lymphoid cells (ILC3) in mice. Methods The bioinformatics was used to analyze the expression of CD226 on murine ILCs. Small intestinal mucosal lamina propria lymphocytes (LPL) were isolated from wild-type C57BL/6J mice, and the expression of CD226 on ILC1 and ILC3 was detected by flow cytometry. A mouse model of dextran sulfate sodium (DSS)-induced colitis was constructed to observe the changes in the expression of CD226 on ILC3. Results Both ILC1 and ILC3 in the mice small intestine expressed CD226 molecules; the proportion of ILC3 was reduced, while the expression level of CD226 on ILC3 was increased in the colitis model. Conclusion CD226 is expressed on the small intestines of mice, and although the proportion of ILC3 decreases in the DSS-induced colitis, the expression of CD226 on ILC3 increases.
Animals
;
Mice
;
Colitis/chemically induced*
;
Immunity, Innate
;
Intestine, Small
;
Lymphocytes
;
Mice, Inbred C57BL
4.Advances in Modeling of Multiple Myeloma in Mice.
Xin-Yuan GU ; Wen-Jiao TANG ; Yan LI ; Li ZHANG ; Yu-Huan ZHENG
Acta Academiae Medicinae Sinicae 2023;45(3):512-518
Multiple myeloma(MM)is a systemic malignancy of plasma cells.Nowadays,the basic research on MM is flourishing with the continuous optimization and innovation of mouse models of MM.Heterologous mouse models of MM established with human-derived cells and immunodeficient mice have been applied in assessing drug efficacy,exploring drug resistance mechanisms,and observing tumor-bone marrow microenvironment interactions.In the last decades,the homologous mouse models of MM established with murine-derived cells or gene-editing technologies have been widely used in the research on the pathogenesis and drug development.Additionally,the stable modeling of targeted organ injury will be a key problem to be tackled in this field.This review summarizes the characteristics and application progress of mouse models of MM.
Humans
;
Animals
;
Mice
;
Multiple Myeloma/pathology*
;
Bone Marrow/pathology*
;
Disease Models, Animal
;
Drug Resistance
;
Tumor Microenvironment
5.Progress in research of epidemiology of 2019-nCoV reinfection.
Chun Xiao LIAO ; Bo WANG ; Jun LYU ; Li Ming LI
Chinese Journal of Epidemiology 2023;44(3):360-366
Continuous evolution of Omicron variant of 2019-nCoV has resulted in a rapid and simultaneous emergences of novel sub-variants with increased immune escape ability, higher reinfection risk and shorter time interval between infections. Compared with the first infection, the reinfection would still pose exceed risk to people's health although the clinical manifestations of the reinfection might be milder and the risk for severe illness or death is lower. The reinfection is highly associated with people's vaccination status, immunity level, age, working and residential factors. Those who have not received 2019-nCoV vaccination, the elderly and those with comorbidities, especially the previous 2019-nCoV patients with severe/critical illness, are at high risk for the reinfection. Booster doses of vaccine might play an additional role in the prevention of the reinfection and severe illness on the basis of natural immunity.
Aged
;
Humans
;
COVID-19
;
Reinfection/epidemiology*
;
SARS-CoV-2
;
Immunity, Innate
6.Update on the role and mechanism of erythropoietin receptor in acute kidney injury and repair or fibrosis.
Cheng HAN ; Yu LIU ; Yuan-Yuan WU ; Bin YANG
Acta Physiologica Sinica 2023;75(1):115-129
Acute kidney injury (AKI) is a common critical disease clinically with high morbility and mortality and some survival patients also progress to chronic kidney disease. Renal ischemia-reperfusion (IR) is one of the main causes of AKI, in which, its repair and potential fibrosis, apoptosis, inflammation and phagocytosis play important roles. During the progression of IR-induced AKI, the expression of erythropoietin homodimer receptor (EPOR)2 and EPOR and β common receptor formed heterodimer receptor (EPOR/βcR) is changed dynamically. Moreover, (EPOR)2 and EPOR/βcR may synergistically participate in renoprotection at the stage of AKI and early repair, whereas at the late stage of AKI, the (EPOR)2 induces renal fibrosis and the EPOR/βcR facilitates repair and remodelling. The underlying mechanism, signaling pathways and the different effect turning point of (EPOR)2 and EPOR/βcR have not been well defined. It has been reported that EPO, according to its 3D structure, derived helix B surface peptide (HBSP) and cyclic HBSP (CHBP) only bind to EPOR/βcR. Synthesized HBSP, therefore, provides an effective tool to distinguish the different roles and mechanisms of both receptors, with the (EPOR)2 promoting fibrosis or the EPOR/βcR leading to repair/remodelling at the late stage of AKI. This review discusses the similarities and differences of (EPOR)2 and EPOR/βcR in their impacts on apoptosis, inflammation and phagocytosis in AKI, repair and fibrosis post IR, associated mechanisms, signaling pathways and outcomes.
Humans
;
Receptors, Erythropoietin
;
Acute Kidney Injury
;
Apoptosis
;
Inflammation
;
Phagocytosis
;
Reperfusion Injury
7.Research progress on chemical constituents of Schisandra chinensis and its effect on nonalcoholic fatty liver disease.
Xin-Lu MU ; Bin LI ; Yu-Cen ZOU ; Jiu-Shi LIU ; Ben-Gang ZHANG ; Pei-Gen XIAO ; Hai-Tao LIU
China Journal of Chinese Materia Medica 2023;48(4):861-878
Schisandra chinensis, a traditional Chinese medicinal herb, is rich in chemical constituents, including lignans, triterpenes, polysaccharides, and volatile oils. Clinically, it is commonly used to treat cardiovascular, cerebrovascular, liver, gastrointestinal, and respiratory diseases. Modern pharmacological studies have shown that S. chinensis extract and monomers have multiple pharmacological activities in lowering liver fat, alleviating insulin resistance, and resisting oxidative stress, and have good application prospects in alleviating nonalcoholic fatty liver disease(NAFLD). Therefore, this study reviewed the research progress on chemical constituents of S. chinensis and its effect on NAFLD in recent years to provide references for the research on S. chinensis in the treatment of NAFLD.
Non-alcoholic Fatty Liver Disease
;
Schisandra
;
Insulin Resistance
;
Lignans
8.Changes and significance of type 2 innate lymphoid cells and their related factors in bronchopulmonary dysplasia.
Qian-Wen WANG ; Yue ZHU ; Qiu-Xia WANG ; Hong-Yan LU
Chinese Journal of Contemporary Pediatrics 2023;25(2):179-185
OBJECTIVES:
To investigate the changes and significance of type 2 innate lymphoid cells (ILC2), interleukin-33 (IL-33), interleukin-25 (IL-25), thymic stromal lymphopoietin (TSLP), interleukin-5 (IL-5), and interleukin-13 (IL-13) in peripheral blood of preterm infants with bronchopulmonary dysplasia (BPD).
METHODS:
A total of 76 preterm infants with a gestational age of <32 weeks and a length of hospital stay of ≥14 days who were admitted to the Department of Pediatrics of the Affiliated Hospital of Jiangsu University from September 2020 to December 2021 were enrolled. According to the diagnostic criteria for BPD, they were divided into a BPD group with 30 infants and a non-BPD group with 46 infants. The two groups were compared in terms of the percentage of ILC2 and the levels of IL-33, IL-25, TSLP, IL-5, and IL-13 in peripheral blood on days 1, 7, and 14 after birth.
RESULTS:
The BPD group had significantly lower birth weight and gestational age than the non-BPD group (P<0.05). On days 7 and 14 after birth, the BPD group had significantly higher levels of ILC2, IL-33, TSLP, and IL-5 than the non-BPD group (P<0.05), and these indices had an area under the curve of >0.7 in predicting the devolpment of BPD (P<0.05). Multivariate logistic regression analysis showed that after adjusting for gestational age and birth weight, peripheral blood IL-33, TSLP and IL-5 on days 7 and 14 after birth were closely related to the devolpment of BPD (P<0.05).
CONCLUSIONS
Early innate immune activation and upregulated expression of related factors may be observed in preterm infants with BPD. ILC2, IL-33, TSLP, and IL-5 may be used as biological indicators for early diagnosis of BPD.
Child
;
Humans
;
Infant
;
Infant, Newborn
;
Birth Weight
;
Bronchopulmonary Dysplasia/pathology*
;
Cytokines
;
Immunity, Innate
;
Infant, Premature
;
Interleukin-13
;
Interleukin-33
;
Interleukin-5
;
Lymphocytes/pathology*
;
Thymic Stromal Lymphopoietin
9.Astrocyte-Mediated Myelin Phagocytosis in Ischemia.
Luodan YANG ; Dongyu ZHANG ; Quanguang ZHANG
Neuroscience Bulletin 2023;39(1):167-169
Humans
;
Myelin Sheath
;
Astrocytes
;
Phagocytosis
;
Macrophages
;
Ischemia
10.Modulation of type I interferon signaling by natural products in the treatment of immune-related diseases.
Shuo LI ; Guifang FAN ; Xiaojiaoyang LI ; Yajie CAI ; Runping LIU
Chinese Journal of Natural Medicines (English Ed.) 2023;21(1):3-18
Type I interferon (IFN) is considered as a bridge between innate and adaptive immunity. Proper activation or inhibition of type I IFN signaling is essential for host defense against pathogen invasion, tumor cell proliferation, and overactive immune responses. Due to intricate and diverse chemical structures, natural products and their derivatives have become an invaluable source inspiring innovative drug discovery. In addition, some natural products have been applied in clinical practice for infection, cancer, and autoimmunity over thousands of years and their promising curative effects and safety have been well-accepted. However, whether these natural products are primarily targeting type I IFN signaling and specific molecular targets involved are not fully elucidated. In the current review, we thoroughly summarize recent advances in the pharmacology researches of natural products for their type I IFN activity, including both agonism/activation and antagonism/inhibition, and their potential application as therapies. Furthermore, the source and chemical nature of natural products with type I IFN activity are highlighted and their specific molecular targets in the type I IFN pathway and mode of action are classified. In conclusion, natural products possessing type I IFN activity represent promising therapeutic strategies and have a bright prospect in the treatment of infection, cancer, and autoimmune diseases.
Biological Products/therapeutic use*
;
Immunity, Innate
;
Signal Transduction
;
Interferon Type I/metabolism*

Result Analysis
Print
Save
E-mail